Cytori Therapeutics, Inc. (CYTX) Receives 510(k) Clearance from the FDA on Puregraft 850
Cytori Therapeutics is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. The company believes ADRCs improve blood flow, moderate the immune response, and keep at-risk tissues from dying. The company announced today that it has received 510 (k) clearance from the U.S. Food and Drug Administration for the Puregraft 850 system for body contouring using a patient's own fat. It had already received European clearance. This product line extension from Cytori provides optimized and sterile processing in only 15 minutes of up to 850 milliliters of tissue. Cytori's best-in-class…